



Identification of Candidate Genes in Breast and Ovarian Cancer

Guest Editors:

Dr. Nadège Presneau

University of Westminster, Cancer Research Group, School of Life Sciences, College of Liberal Arts & Sciences, London, United Kingdom

Prof. BIGNON Yves-Jean

Centre Jean Perrin, INSERM 1240, Université Clermont Auvergne, France

Dr. Pinar Uysal-Onganer

Cancer Research Group, School of Life Sciences, College of Liberal Arts & Sciences, University of Westminster, London, UK

Deadline for manuscript submissions:

closed (31 August 2021)

Message from the Guest Editors

Dear Colleagues,

On a global scale, breast cancer is the most frequently diagnosed cancer in women; there were over 2 million new cases in 2018, contributing to about 11.6% of the total cancer incidence burden (Globocan 2018, International Agency for Research on Cancer). However, although the last decade has seen an increase in breast cancer incidence, there have also been great improvements in its diagnosis and survival with nearly 80% of breast cancer patients surviving for at least 10 years (Cancer Research UK). According to the International Agency for Research on Cancer, in 2018, female breast cancer ranked as the fifth leading cause of death (627,000 deaths, 6.6%) due to the prognosis being relatively favourable, at least in more developed countries.

Novel therapeutics, such as Herceptin (trastuzumab), and hormone-related biological therapies have greatly contributed to the increased survival rate, as has the knowledge acquired in cancer biology, particularly regarding the identification of candidate genes using molecular and computational approaches to interpret the “OMICs” big data generated principally by genomics and transcriptomics.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)